India has not added Merck's Covid-19 pill to its national treatment protocol for the disease due to known safety concerns that have restricted its use elsewhere, a senior health official told a media briefing.

“We have to remember that this drug has major safety concerns,” Balram Bhargava, head of the state-run Indian Council of Medical Research, said, reports Reuters.

“It can cause teratogenicity, mutagenicity and it also can cause cartilage damage and be damaging to muscles. More importantly, contraception will have to be used for three months if this drug is given because the child born could be problematic with teratogenic influences.”

Opinion

Editorial

Sustainable path?
Updated 13 Jun, 2026

Sustainable path?

The FY27 budget is the first clear signal that the government is ready to transition from stabilisation to growth.
Prioritising education
13 Jun, 2026

Prioritising education

THOUGH the improvement in the country’s literacy rate may be slight, as highlighted by the Economic Survey, it ...
Poverty’s rise
13 Jun, 2026

Poverty’s rise

AS attention turns to the government’s plans for the coming fiscal year, one set of figures deserves particular...
A difficult story
Updated 12 Jun, 2026

A difficult story

Unless productivity becomes the dominant target of economic policy, Pakistan will continue to oscillate between crises and fragile recovery.
Rough waters
12 Jun, 2026

Rough waters

AMONGST the key potential triggers for fresh conflict in South Asia is water. The Indian state is behaving in an...
Politicised football
12 Jun, 2026

Politicised football

ALMOST three-and-half years since Lionel Messi led Argentina to FIFA World Cup glory, the latest edition of...